Clorom XL 500 mg Prolonged-Release Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

clorom xl 500 mg prolonged-release tablets

morningside healthcare ltd - clarithromycin - prolonged-release tablet - 500 milligram(s) - macrolides; clarithromycin

Klacid Forte 500 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klacid forte 500 mg film-coated tablets

pco manufacturing ltd. - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Klacid LA 500 mg modified-release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klacid la 500 mg modified-release tablets

pco manufacturing ltd. - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin

Klariger 500 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klariger 500 mg film-coated tablets

mcdermott laboratories ltd., t/a gerard laboratories - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Klacid Forte 500 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klacid forte 500 mg film-coated tablets

mylan ire healthcare limited - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections due to susceptible organisms. such infections include. 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. is indicated also for the prevention of disseminated mycobacterium avium complex infection in hiv- infected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer.

Klacid IV 500mg Powder for Concentrate for Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

klacid iv 500mg powder for concentrate for solution for infusion

mylan ire healthcare limited - clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms in the following conditions: lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. upper respiratory tract infections for example, sinusitis and pharyngitis. skin and soft tissue infections.

Klacid 250 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klacid 250 mg film-coated tablets

mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).

Klacid LA 500mg Modified release tablets Ireland - English - HPRA (Health Products Regulatory Authority)

klacid la 500mg modified release tablets

mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include:  lower respiratory tract infections for example bronchitis and pneumonia.  upper respiratory tract infections for example sinusitis and pharyngitis.  skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.

Klacid Paediatric Suspension 125mg/5ml, Granules for Oral Suspension Ireland - English - HPRA (Health Products Regulatory Authority)

klacid paediatric suspension 125mg/5ml, granules for oral suspension

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 125 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include o lower respiratory tract infections o upper respiratory tract infections o skin and skin structure infections o acute otitis media

Klacid 250mg/5ml Granules for Oral Suspension Ireland - English - HPRA (Health Products Regulatory Authority)

klacid 250mg/5ml granules for oral suspension

mylan ire healthcare limited - clarithromycin - granules for oral suspension - 250 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections. upper respiratory tract infections. skin and skin structure infections. acute otitis media.